Böck Desiree, Wilhelm Maria, Mumenthaler Jonas, Carpanese Daniel Fabio, Kulcsár Peter I, d'Aquin Simon, Cremonesi Alessio, Rassi Anahita, Häberle Johannes, Patriarchi Tommaso, Schwank Gerald
Institute of Pharmacology and Toxicology, University of Zurich, Zurich, Switzerland.
Division of Clinical Chemistry and Biochemistry, University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland.
Elife. 2024 Dec 23;13:RP97180. doi: 10.7554/eLife.97180.
Parkinson's disease (PD) is a multifactorial disease caused by irreversible progressive loss of dopaminergic neurons (DANs). Recent studies have reported the successful conversion of astrocytes into DANs by repressing polypyrimidine tract binding protein 1 (PTBP1), which led to the rescue of motor symptoms in a chemically-induced mouse model of PD. However, follow-up studies have questioned the validity of this astrocyte-to-DAN conversion model. Here, we devised an adenine base editing strategy to downregulate PTBP1 in astrocytes and neurons in a chemically-induced PD mouse model. While PTBP1 downregulation in astrocytes had no effect, PTBP1 downregulation in neurons of the striatum resulted in the expression of the DAN marker tyrosine hydroxylase (TH) in non-dividing neurons, which was associated with an increase in striatal dopamine concentrations and a rescue of forelimb akinesia and spontaneous rotations. Phenotypic analysis using multiplexed iterative immunofluorescence imaging further revealed that most of these TH-positive cells co-expressed the dopaminergic marker DAT and the pan-neuronal marker NEUN, with the majority of these triple-positive cells being classified as mature GABAergic neurons. Additional research is needed to fully elucidate the molecular mechanisms underlying the expression of the observed markers and understand how the formation of these cells contributes to the rescue of spontaneous motor behaviors. Nevertheless, our findings support a model where downregulation of neuronal, but not astrocytic, PTBP1 can mitigate symptoms in PD mice.
帕金森病(PD)是一种由多巴胺能神经元(DANs)不可逆的进行性丧失引起的多因素疾病。最近的研究报道,通过抑制多嘧啶序列结合蛋白1(PTBP1),可成功将星形胶质细胞转化为DANs,这在化学诱导的PD小鼠模型中挽救了运动症状。然而,后续研究对这种星形胶质细胞向DAN转化模型的有效性提出了质疑。在此,我们设计了一种腺嘌呤碱基编辑策略,以在化学诱导的PD小鼠模型中下调星形胶质细胞和神经元中的PTBP1。虽然星形胶质细胞中PTBP1的下调没有效果,但纹状体神经元中PTBP1的下调导致非分裂神经元中DAN标志物酪氨酸羟化酶(TH)的表达,这与纹状体多巴胺浓度的增加以及前肢运动不能和自发旋转的挽救有关。使用多重迭代免疫荧光成像进行的表型分析进一步表明,这些TH阳性细胞中的大多数共表达多巴胺能标志物DAT和泛神经元标志物NEUN,这些三阳性细胞中的大多数被归类为成熟的GABA能神经元。需要进一步的研究来充分阐明观察到的标志物表达背后的分子机制,并了解这些细胞的形成如何有助于挽救自发运动行为。尽管如此,我们的研究结果支持一种模型,即神经元而非星形胶质细胞中PTBP1的下调可以减轻PD小鼠的症状。